Literature DB >> 25228413

BRAF activates and physically interacts with PAK to regulate cell motility.

Samantha K McCarty1, Motoyasu Saji1, Xiaoli Zhang1, Christina M Knippler1, Lawrence S Kirschner2, Soledad Fernandez1, Matthew D Ringel3.   

Abstract

Increased p21-activated kinase (PAK) signaling and expression have been identified in the invasive fronts of aggressive papillary thyroid cancers (PTCs), including those with RET/PTC, BRAFV600E, and mutant RAS expression. Functionally, thyroid cancer cell motility in vitro is dependent on group 1 PAKs, particularly PAK1. In this study, we hypothesize that BRAF, a central kinase in PTC tumorigenesis and invasion, regulates thyroid cancer cell motility in part through PAK activation. Using three well-characterized human thyroid cancer cell lines, we demonstrated in all cell lines that BRAF knockdown reduced PAK phosphorylation of direct downstream targets. In contrast, inhibition of MEK activity either pharmacologically or with siRNA did not reduce PAK activity, indicating MEK is dispensable for PAK activity. Inhibition of cell migration through BRAF loss is rescued by overexpression of either constitutive active MEK1 or PAK1, demonstrating that both signaling pathways are involved in BRAF-regulated cell motility. To further characterize BRAF-PAK signaling, immunofluorescence and immunoprecipitation demonstrated that both exogenously overexpressed and endogenous PAK1 and BRAF co-localize and physically interact, and that this interaction was enhanced in mitosis. Finally, we demonstrated that acute induction of BRAFV600E expression in vivo in murine thyroid glands results in increased PAK expression and activity confirming a positive signaling relationship in vivo. In conclusion, we have identified a signaling pathway in thyroid cancer cells which BRAF activates and physically interacts with PAK and regulates cell motility.
© 2014 Society for Endocrinology.

Entities:  

Keywords:  BRAF; PAK1; cancer biology; cell motility; thyroid cancer

Mesh:

Substances:

Year:  2014        PMID: 25228413      PMCID: PMC4487662          DOI: 10.1530/ERC-14-0424

Source DB:  PubMed          Journal:  Endocr Relat Cancer        ISSN: 1351-0088            Impact factor:   5.678


  49 in total

1.  Oncogenic BRAF induces melanoma cell invasion by downregulating the cGMP-specific phosphodiesterase PDE5A.

Authors:  Imanol Arozarena; Berta Sanchez-Laorden; Leisl Packer; Cristina Hidalgo-Carcedo; Robert Hayward; Amaya Viros; Erik Sahai; Richard Marais
Journal:  Cancer Cell       Date:  2011-01-06       Impact factor: 31.743

2.  p21-activated kinase 1 (PAK1) can promote ERK activation in a kinase-independent manner.

Authors:  Zhipeng Wang; Meng Fu; Lifeng Wang; Juanjuan Liu; Yuhua Li; Cord Brakebusch; Qibing Mei
Journal:  J Biol Chem       Date:  2013-05-07       Impact factor: 5.157

3.  Growth regulation of normal thyroids and thyroid tumors in man.

Authors:  P E Goretzki; A Frilling; D Simon; H D Roeher
Journal:  Recent Results Cancer Res       Date:  1990

4.  Gene expression and functional evidence of epithelial-to-mesenchymal transition in papillary thyroid carcinoma invasion.

Authors:  Vasily Vasko; Allan V Espinosa; William Scouten; Huiling He; Herbert Auer; Sandya Liyanarachchi; Alexander Larin; Victoria Savchenko; Gary L Francis; Albert de la Chapelle; Motoyasu Saji; Matthew D Ringel
Journal:  Proc Natl Acad Sci U S A       Date:  2007-02-12       Impact factor: 11.205

5.  Colocalization of fluorescent markers in confocal microscope images of plant cells.

Authors:  Andrew P French; Steven Mills; Ranjan Swarup; Malcolm J Bennett; Tony P Pridmore
Journal:  Nat Protoc       Date:  2008       Impact factor: 13.491

Review 6.  BRAF mutation in papillary thyroid cancer: pathogenic role, molecular bases, and clinical implications.

Authors:  Mingzhao Xing
Journal:  Endocr Rev       Date:  2007-10-16       Impact factor: 19.871

7.  Localization of CaSR antagonists in CaSR-expressing medullary thyroid cancer.

Authors:  Haiming Ding; Adlina Mohd Yusof; Shankaran Kothandaraman; Motoyasu Saji; Chaojie Wang; Krishan Kumar; Keisha Milum; Michelle Carleton; Xueliang Pan; Matthew D Ringel; Michael F Tweedle; John E Phay
Journal:  J Clin Endocrinol Metab       Date:  2013-09-12       Impact factor: 5.958

8.  Phase II trial of sorafenib in metastatic thyroid cancer.

Authors:  Richard T Kloos; Matthew D Ringel; Michael V Knopp; Nathan C Hall; Mark King; Robert Stevens; Jiachao Liang; Paul E Wakely; Vasyl V Vasko; Motoyasu Saji; Jennifer Rittenberry; Lai Wei; Daria Arbogast; Minden Collamore; John J Wright; Michael Grever; Manisha H Shah
Journal:  J Clin Oncol       Date:  2009-03-02       Impact factor: 44.544

9.  Worldwide increasing incidence of thyroid cancer: update on epidemiology and risk factors.

Authors:  Gabriella Pellegriti; Francesco Frasca; Concetto Regalbuto; Sebastiano Squatrito; Riccardo Vigneri
Journal:  J Cancer Epidemiol       Date:  2013-05-07

10.  Vemurafenib enhances MHC induction in BRAFV600E homozygous melanoma cells.

Authors:  Bishu Sapkota; Charles E Hill; Brian P Pollack
Journal:  Oncoimmunology       Date:  2013-01-01       Impact factor: 8.110

View more
  8 in total

Review 1.  Coding Molecular Determinants of Thyroid Cancer Development and Progression.

Authors:  Veronica Valvo; Carmelo Nucera
Journal:  Endocrinol Metab Clin North Am       Date:  2018-12-23       Impact factor: 4.741

Review 2.  p21-Activated Kinases in Thyroid Cancer.

Authors:  Luis Bautista; Christina M Knippler; Matthew D Ringel
Journal:  Endocrinology       Date:  2020-08-01       Impact factor: 4.736

3.  P21-activated kinase 1 regulates resistance to BRAF inhibition in human cancer cells.

Authors:  Mahamat Babagana; Sydney Johnson; Hannah Slabodkin; Wiam Bshara; Carl Morrison; Eugene S Kandel
Journal:  Mol Carcinog       Date:  2017-02-23       Impact factor: 4.784

4.  MAPK- and AKT-activated thyroid cancers are sensitive to group I PAK inhibition.

Authors:  Christina M Knippler; Motoyasu Saji; Neel Rajan; Kyle Porter; Krista M D La Perle; Matthew D Ringel
Journal:  Endocr Relat Cancer       Date:  2019-08       Impact factor: 5.678

Review 5.  Progression and dormancy in metastatic thyroid cancer: concepts and clinical implications.

Authors:  Neel Rajan; Tilak Khanal; Matthew D Ringel
Journal:  Endocrine       Date:  2020-08-11       Impact factor: 3.633

6.  Oncogenic BRAF disrupts thyroid morphogenesis and function via twist expression.

Authors:  Viviana Anelli; Jacques A Villefranc; Sagar Chhangawala; Raul Martinez-McFaline; Eleonora Riva; Anvy Nguyen; Akanksha Verma; Rohan Bareja; Zhengming Chen; Theresa Scognamiglio; Olivier Elemento; Yariv Houvras
Journal:  Elife       Date:  2017-03-28       Impact factor: 8.140

7.  RAC1 Alterations Induce Acquired Dabrafenib Resistance in Association with Anaplastic Transformation in a Papillary Thyroid Cancer Patient.

Authors:  Rozita Bagheri-Yarmand; Naifa L Busaidy; Elena McBeath; Brian P Danysh; Kurt W Evans; Tyler J Moss; Argun Akcakanat; Patrick K S Ng; Christina M Knippler; Jalyn A Golden; Michelle D Williams; Asha S Multani; Maria E Cabanillas; Kenna R Shaw; Funda Meric-Bernstam; Manisha H Shah; Matthew D Ringel; Marie Claude Hofmann
Journal:  Cancers (Basel)       Date:  2021-09-30       Impact factor: 6.575

Review 8.  P21-Activated Kinase 1: Emerging biological functions and potential therapeutic targets in Cancer.

Authors:  Dahong Yao; Chenyang Li; Muhammad Shahid Riaz Rajoka; Zhendan He; Jian Huang; Jinhui Wang; Jin Zhang
Journal:  Theranostics       Date:  2020-08-01       Impact factor: 11.556

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.